FINANCIERE DE TUBIZE

Overview

Financière de Tubize is a Belgian mono-holding company whose sole investment is UCB; it has no commercial or industrial operations of its own [1]. At 31 December 2025, it held 36.28% of UCB’s issued shares and reported total assets of €1.934 billion [2]. Tubize’s role is to act as UCB’s long-term reference shareholder, contributing to its strategy and supporting stability for long-term investment [3][4].

UCB, rather than Tubize, is the operating biopharmaceutical company, focused on immunology and neurology, with a presence in nearly 40 countries [5][6]. Tubize’s stated purpose includes generating long-term shareholder returns, supporting UCB’s development of treatments for serious illnesses, and fostering a sustainable biopharma ecosystem [7][8]. Tubize reported no employees; for operating scale, UCB reported 2025 revenue of €7.741 billion and 10,117 employees [9][6]. [1]+9

Products & services

Financière de Tubize does not itself market products or provide commercial services: it is a mono-holding company with no commercial or industrial activity, and its sole investment is UCB [1]. Its role is as a long-term shareholder; at 31 December 2025 it held 36.28% of UCB’s issued shares [10].

The medicines associated with Tubize are products of its investee UCB, not of Tubize. Products named in Tubize’s 2025 reporting include BIMZELX, FINTEPLA, RYSTIGGO and ZILBRYSQ [11]. UCB describes BIMZELX (bimekizumab) as an IL‑17A and IL‑17F inhibitor [12]; FINTEPLA (fenfluramine) is used for seizures associated with Dravet and Lennox–Gastaut syndromes [13]; and RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) are treatments for generalized myasthenia gravis [14][15]. No product-sales mix or product contribution to performance applies directly to Tubize, which has no product sales of its own. [1]+10

Geographic presence

Financière de Tubize is a mono-holding company with no commercial or industrial activity; its geographic exposure is through its 36.28% holding in UCB at 31 December 2025, rather than a separately reported operating or sales footprint [1][10]. [1][10]

Business segments

Financière de Tubize’s FY2025 reporting describes it as a holding company whose core focus is the long-term holding in UCB, an innovative global biopharmaceutical business. At 31 December 2025, Tubize held 36.28% of UCB’s issued shares.[3]+2

Tubize does not report business segments or segment contribution percentages: it states that it is not required to prepare consolidated accounts, and its statutory company accounts do not provide an operating-segment breakdown. Accordingly, no segment percentages are disclosed.[16] [3]+4

Company history

Financière de Tubize dates to 1928. Company records describe Tubize as becoming part of the Janssen family that year; UCB was also created in 1928, as a separate milestone, by Emmanuel Janssen.[18]+2

Tubize first became a UCB shareholder in 1961. It substantially increased its position in 1981 by acquiring half of Rhône-Poulenc’s UCB securities, while Royale Belge acquired the other half. After gradually taking over Royale Belge’s UCB shares, Tubize’s holding reached 40% in 2002.[20]+2

In 2006, Tubize borrowed €100 million to participate in a UCB capital increase supporting UCB’s acquisition of Schwarz Pharma. On 25 April 2025, Bruno Holthof became chair of Tubize, succeeding Gaëtan Hannecart.[23][24] [18]+7

Sources

• FINANCIERE DE TUBIZE — Full financial report (2025 Y)
  17 citations

  [1][2][3][4][5][7][8][9][10][11][16][18][19][20][21][22][23]
• www.ucb.com[6]
• www.ucb.com[12]
• www.ucb.com[13]
• www.ucb.com[14]
• www.ucb.com[15]
• www.financiere-tubize.be[17]
• www.financiere-tubize.be[24]